Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low - Should You Sell?

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low as $17.41 and last traded at $17.75, with a volume of 36032 shares traded. The stock had previously closed at $18.05.

Analyst Ratings Changes

A number of analysts have recently issued reports on BCAX shares. RODMAN&RENSHAW upgraded Bicara Therapeutics to a "strong-buy" rating in a research report on Tuesday, November 5th. Morgan Stanley initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 price objective for the company. TD Cowen initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a "buy" rating on the stock. HC Wainwright assumed coverage on shares of Bicara Therapeutics in a research note on Friday, December 6th. They issued a "buy" rating and a $42.00 target price on the stock. Finally, Stifel Nicolaus began coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a "buy" rating and a $47.00 price target for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $43.00.

Bicara Therapeutics Stock Performance

The company has a fifty day moving average price of $21.21.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Equities analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder James E. Flynn bought 70,000 shares of the company's stock in a transaction on Tuesday, September 17th. The stock was bought at an average cost of $18.00 per share, with a total value of $1,260,000.00. Following the completion of the purchase, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. The trade was a 8.46 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the firm's stock in a transaction dated Monday, September 16th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the purchase, the director now directly owns 4,303,418 shares of the company's stock, valued at $77,461,524. The trade was a 74.20 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Cinctive Capital Management LP bought a new stake in Bicara Therapeutics during the 3rd quarter worth about $229,000. Barclays PLC acquired a new stake in shares of Bicara Therapeutics during the 3rd quarter worth approximately $255,000. Jane Street Group LLC bought a new stake in shares of Bicara Therapeutics during the third quarter worth approximately $309,000. Teachers Retirement System of The State of Kentucky acquired a new position in Bicara Therapeutics in the third quarter valued at approximately $358,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Bicara Therapeutics in the third quarter valued at approximately $462,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.